{"name":"Develco Pharma Schweiz AG","slug":"develco-pharma-schweiz-ag","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Naloxone HCl PR tablets","genericName":"Naloxone HCl PR tablets","slug":"naloxone-hcl-pr-tablets","indication":"Opioid overdose reversal","status":"phase_3"}]}],"pipeline":[{"name":"Naloxone HCl PR tablets","genericName":"Naloxone HCl PR tablets","slug":"naloxone-hcl-pr-tablets","phase":"phase_3","mechanism":"Naloxone HCl is a competitive opioid receptor antagonist that blocks the effects of opioids by binding to opioid receptors without activating them.","indications":["Opioid overdose reversal","Opioid use disorder maintenance treatment","Prevention of opioid overdose in at-risk populations"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE5ubVFKYmFhTUhka0tONlpVeWRiVm5uTXNJX3pmeEhpcHlmZXNMQW9sZENmRmVXLWdfMFE3NUE1N3UtUVdnVGRKb0J2SGdlVDdMbXNkaHpnT1RYMnJkMmpFTUVsdDdtWTBuRDBxTF90eVVtTWxkYS1raEtR?oc=5","date":"2023-08-17","type":"trial","source":"drugdiscoverytrends.com","summary":"Ketabon KET01 Treatment-Resistant Depression: Phase 2 findings - drugdiscoverytrends.com","headline":"Ketabon KET01 Treatment-Resistant Depression: Phase 2 findings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNMDZJR0xEU1FQUExCWXREc1NoY2tZQjRDd3RZQUc4d0NqZTZCMUNxd2UzeTZVRXhwLTVseUV0alBzQlBLa1lQTl9aaTA4OWxPRzBucXFpTGViWnRnMi1rRWhCT1owSHhGZG9ONHgtRXREdm9RanhUeXE0NDZkNjBvSTRQVFl2WGYzNm9KQlh3?oc=5","date":"2022-06-06","type":"pipeline","source":"Mugglehead Magazine","summary":"U.S. psychedelic drug market to reach $8.9B by 2029: DBMR report - Mugglehead Magazine","headline":"U.S. psychedelic drug market to reach $8.9B by 2029: DBMR report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQejZuczZHMnlvanhaU3FydmgzWWl4QVN0WEYxc0hnd3lKdGU1MXBZaVd3R0xtYzNiYkt0Z2FNNW5YR1cyQmxvMDVEU3NCMUpicENhLW55czc1cmhveVhrdWhnMkNpaDdTVFQ3c2hxRzNPNHhQZGxYYTZVcjBCcWotZXFoazU1QkFYb2xKSl9heUtERl8yMm4yN2tB?oc=5","date":"2020-06-06","type":"pipeline","source":"openPR.com","summary":"Psychedelic Drugs Market 2020 to Grow at +16.3% CAGR by 2027 - openPR.com","headline":"Psychedelic Drugs Market 2020 to Grow at +16.3% CAGR by 2027","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}